Post by Terumo Pharmaceutical Solutions Division

4,749 followers

๐—Ÿ๐—ฒ๐—ฎ๐—ฑ๐—ฒ๐—ฟ๐˜€๐—ต๐—ถ๐—ฝ ๐—™๐—ผ๐—ฐ๐˜‚๐˜€: ๐—œ๐—ป๐˜€๐—ถ๐—ด๐—ต๐˜๐˜€ ๐—ณ๐—ฟ๐—ผ๐—บ ๐—™๐˜‚๐—ท๐—ถ๐˜๐—ฎ ๐—ก๐—ผ๐—ฟ๐—ถ๐˜๐˜€๐˜‚๐—ด๐˜‚ In the fifth instalment of our interview series, Noritsugu Fujita discusses how Terumo Pharmaceutical Solutions Division's focus on sustainable growth, quality, and long-term partnerships helps create value for both customers and patients. Fujita shares how an integrated CDMO model, combined with deep device expertise and a commitment to quality, helps support efficient development and long-term success. ๐ŸŽฌWatch the video to find out more. #TerumoPharmaceuticalSolutionsDivision #CDMO #LeadershipInsights #PharmaceuticalTechnology

Post content

Video Content